Plasmacytoid dendritic cells proliferation ...
Type de document :
Compte-rendu et recension critique d'ouvrage
Titre :
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Auteur(s) :
Zalmaï, Loria [Auteur]
Viailly, Pierre-Julien [Auteur]
Biichle, Sabeha [Auteur]
Cheok, Meyling [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Soret, Lou [Auteur]
Angelot-Delettre, Fanny [Auteur]
Petrella, Tony [Auteur]
Collonge-Rame, Marie-Agnès [Auteur]
Seilles, Estelle [Auteur]
Geffroy, Sandrine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Deconinck, Eric [Auteur]
Daguindau, Etienne [Auteur]
Bouyer, Sabrina [Auteur]
Dindinaud, Elodie [Auteur]
Baunin, Victor [Auteur]
Le Garff-Tavernier, Magali [Auteur]
Roos-Weil, Damien [Auteur]
Wagner-Ballon, Orianne [Auteur]
Salaun, Véronique [Auteur]
Feuillard, Jean [Auteur]
Brun, Sophie [Auteur]
Drenou, Bernard [Auteur]
Mayeur-Rousse, Caroline [Auteur]
Okamba, Patricia [Auteur]
Dorvaux, Véronique [Auteur]
Tichionni, Michel [Auteur]
Rose, Johann [Auteur]
Rubio, Marie Thérèse [Auteur]
Jacob, Marie Christine [Auteur]
Raggueneau, Victoria [Auteur]
Preudhomme, Claude [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Saas, Philippe [Auteur]
Ferrand, Christophe [Auteur]
Adotevi, Olivier [Auteur]
Roumier, Christophe [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service de pathologie [CHU Lille]
Jardin, Fabrice [Auteur]
Garnache-Ottou, Francine [Auteur]
Renosi, Florian [Auteur]
Viailly, Pierre-Julien [Auteur]
Biichle, Sabeha [Auteur]
Cheok, Meyling [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Soret, Lou [Auteur]
Angelot-Delettre, Fanny [Auteur]
Petrella, Tony [Auteur]
Collonge-Rame, Marie-Agnès [Auteur]
Seilles, Estelle [Auteur]
Geffroy, Sandrine [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Deconinck, Eric [Auteur]
Daguindau, Etienne [Auteur]
Bouyer, Sabrina [Auteur]
Dindinaud, Elodie [Auteur]
Baunin, Victor [Auteur]
Le Garff-Tavernier, Magali [Auteur]
Roos-Weil, Damien [Auteur]
Wagner-Ballon, Orianne [Auteur]
Salaun, Véronique [Auteur]
Feuillard, Jean [Auteur]
Brun, Sophie [Auteur]
Drenou, Bernard [Auteur]
Mayeur-Rousse, Caroline [Auteur]
Okamba, Patricia [Auteur]
Dorvaux, Véronique [Auteur]
Tichionni, Michel [Auteur]
Rose, Johann [Auteur]
Rubio, Marie Thérèse [Auteur]
Jacob, Marie Christine [Auteur]
Raggueneau, Victoria [Auteur]
Preudhomme, Claude [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Saas, Philippe [Auteur]
Ferrand, Christophe [Auteur]
Adotevi, Olivier [Auteur]
Roumier, Christophe [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service de pathologie [CHU Lille]
Jardin, Fabrice [Auteur]
Garnache-Ottou, Francine [Auteur]
Renosi, Florian [Auteur]
Titre de la revue :
Haematologica
Pagination :
3056-3066
Éditeur :
Ferrata Storti Foundation
Date de publication :
2020-10-13
ISSN :
0390-6078
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other pDC proliferations, where pDC are associated with myeloid malignancies: most frequently chronic myelomonocytic leukemia ...
Lire la suite >Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other pDC proliferations, where pDC are associated with myeloid malignancies: most frequently chronic myelomonocytic leukemia (CMML) but also acute myeloid leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDC in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DC (cDC) associated in the same sample, by phenotypic and molecular analyses (targeted next-generation sequencing, 70 genes). We compared 15 pDCAML at diagnosis with 21 BPDCN and 11 normal pDC from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDC (4-36%), monocytes in 14 cases (1-10%) and cDC (two cases, 4.8-19%). pDC in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56– in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a prepDC stage. In all cases, pDC, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite the low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.Lire moins >
Lire la suite >Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other pDC proliferations, where pDC are associated with myeloid malignancies: most frequently chronic myelomonocytic leukemia (CMML) but also acute myeloid leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDC in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DC (cDC) associated in the same sample, by phenotypic and molecular analyses (targeted next-generation sequencing, 70 genes). We compared 15 pDCAML at diagnosis with 21 BPDCN and 11 normal pDC from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDC (4-36%), monocytes in 14 cases (1-10%) and cDC (two cases, 4.8-19%). pDC in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56– in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a prepDC stage. In all cases, pDC, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite the low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Collections :
Source :